The March issue of Pharma's Almanac features our CEO, Nigel Theobald, discussing the advantages of silica and our work with Nuvec® to improve drug delivery systems for nucleic acid-based cancer immunotherapies and viral vaccines. Click here to read more.
Our CEO, Nigel Theobald, recently provided an update on our Nuvec® program following the release of our interim results. You can watch the full interview with Proactive London's Andrew Scott below or visit the website: https://bit.ly/2lU6O78. https://www.youtube.com/watch?time_continue=776&v=TJVlEOs8TEE
Our CEO, Nigel Theobald, recently caught up with The Medicine Maker to discuss the story behind N4 Pharma and give his advice to entrepreneurs in the pharmaceutical industry. Click here to create your logins and read the full article.
N4 Pharma has been featured in the latest issue of BioPharm International.
We recently joined a full house of attendees at CrownBio’s annual conference.
Nigel Theobald, CEO of N4 Pharma, has spoken to Dr. Kevin Robinson at Manufacturing Chemist magazine about how the company has developed Nuvec® and the impact it could have for vaccines and cancer treatments.
N4 Pharma has been featured in the latest issue of SHARES Magazine.
A unique non-viral adjuvant delivery system for vaccines and cancer treatments.
Allan Hey, Head of CMC, N4 Pharma Ltd, gave a presentation on Nuvec® at the BioNow Oncology Conference on Wednesday 13th February.
N4 Pharma (LON:N4P) is a consumer-driven pharmaceutical company developing reformulations of a number of key drugs.
